Citations in PubMed

Primary Citation PubMed: 11959977 Citations in PubMed

PDB ID Mentions in PubMed Central Article count: 3

Citations in PubMed

This linkout lists citations, indexed by PubMed, to the Primary Citation for this PDB ID.

PDB ID Mentions in PubMed Central

Data mentions are occurrences of PDB IDs in the full text articles from the PubMedCentral Open Access Subset of currently about 1 million articles. For each article, the sentences containing the PDB ID are listed. Article titles can be filtered by keywords and sorted by year.

  • 3 per page
  • 5 per page
  • 10 per page
  • view all
  • Publication Year
  • Ascending
  • Descending

Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

(2013) Curr Pharm Des 19

PubMed: 23016851 | PubMedCentral: PMC3529403 | DOI: null

Available Three-dimensional Structures of Human and Bacterial Human and Bacterial HATs Class Family Name Organism PDB ID Ligand Domain Reference Type A GNAT KAT2A (GCN5) Homo sapiens 1F68 Bromodomain ... 292 ] 1Z4R HAT Domain [ 293 ] 3D7C Bromodomain [ 294 ] Saccharomyces cerevisiae 1E6I Bromodomain [ 295 ] 1YGH HAT Domain [ 296 ] KAT2B (PCAF) Homo sapiens 1CM0 HAT Domain [ 297 ] 1JM4 Bromodomain [ 298 ] 1N72 Bromodomain [ 299 ] 1WUG NP1 Bromodomain [ 300 ] 1WUM NP2 Bromodomain 1ZS5 MIB Bromodomain 2RNW Bromodomain [ 301 ] 2RNX Bromodomain 3GG3 Bromodomain [ 294 ] HPA2 Saccharomyces cerevisiae 1QSM AcCoA HAT Domain [ 302 ] 1QSO HAT Domain p300/ CBP p300 Homo sapiens 1L3E CH1 domain [ 303 ] 1P4Q CH1 domain [ 304 ] 2K8F Taz2 Domain [ 305 ] 3BIY Lys-CoA HAT Domain [ 306 ] 3I3J Bromodomain [ 294 ] 3IO2 Taz2 Domain [ 307 ] 3P57 Taz2 Domain [ 308 ] CBP Homo sapiens 1JSP Bromodomain [ 309 ] 1LIQ CH1 domain [ 310 ] 1WO3 CHANCE Domain (mutate) [ 311 ] 1WO4 CHANCE Domain (mutate) 1WO5 CHANCE Domain (mutate) 1WO6 CHANCE Domain (mutate) 1WO7 CHANCE Domain (mutate) 1ZOQ IRF-3 Binding Domain [ 312 ] 2D82 TTR Bromodomain [ 313 ] 2KJE Taz2 Domain [ 314 ] 2KWF KIX Domain 2L84 J28 Bromodomain [ 315 ] 2L85 L85 Bromodomain 2RNY Bromodomain [ 301 ] 3DWY Bromodomain [ 294 ] 3P1C Bromodomain 3P1D Bromodomain 3P1E DMSO Bromodomain 3P1F 3PF Bromodomain 3SVH KRG Bromodomain 4A9K Tylenol Bromodomain [ 316 ] Mus musculus 1F81 Taz2 Domain [ 317 ] 1JJS IRF-3 Binding Domain [ 318 ] 1KBH IRF-3 Binding Domain [ 319 ] 1KDX KIX Domain [ 320 ] 1L8C Taz1 Domain [ 321 ] 1R8U Taz1 Domain [ 322 ] 1SB0 KIX Domain [ 323 ] 1TOT ZZ Domain [ 324 ] 1U2N Taz1 Domain [ 325 ] 2AGH KIX Domain [ 326 ] 2C52 SRC1 Interaction Domain [ 327 ] 2KA4 Taz1 Domain [ 328 ] 2KA6 Taz2 Domain 2KKJ Nuclear Coactivator Binding Domain [ 329 ] 2L14 Nuclear Coactivator Binding Domain [ 330 ] MYST KAT5 (TIP60) Homo sapiens 2EKO Histone tail binding domain 2OU2 AcCoA HAT Domain KAT6A (MOZ) Homo sapiens 1M36 Zinc Finger Domain 2OZU AcCoA HAT Domain 2RC4 AcCoA HAT Domain [ 331 ] KAT8 (MOF) Homo sapiens 2GIV AcCoA HAT Domain 2PQ8 AcCoA HAT Domain 2Y0M AcCoA HAT Domain [ 332 ] 3QAH HAT Domain [ 333 ] 3TOA HAT Domain [ 334 ] 3TOB HAT Domain (mutate) Mus musculus 1WGS Tudor Domain ESA1 Saccharomyces cerevisiae 1FY7 AcCoA HAT Domain [ 335 ] 1MJ9 AcCoA HAT Domain (mutate) [ 336 ] 1MJA AcCoA HAT Domain 1MJB AcCoA HAT Domain (mutate) 2RNZ Chromodomain [ 337 ] 2RO0 Tudor Domain 3TO6 H4K16CoA HAT Domain [ 334 ] 3TO7 HAT Domain 3TO9 HAT Domain (mutate) Type B HAT1 Homo sapiens 2P0W AcCoA HAT Saccharomyces cerevisiae 1BOB AcCoA HAT [ 338 ] Rtt109 Saccharomyces cerevisiae 2RIM AcCoA HAT [ 339 ] 2ZFN AcCoA HAT 3CZ7 AcCoA HAT [ 340 ] 3Q33 AcCoA HAT [ 341 ] 3Q35 AcCoA HAT 3Q66 AcCoA Full length [ 342 ] 3Q68 AcCoA Full length 3QM0 AcCoA HAT [ 343 ] Table 4.

Publication Year: 2013


Small-molecule proteomimetic inhibitors of the HIF-1?-p300 protein-protein interaction.

(2014) Chembiochem 15

PubMed: 24782431 | PubMedCentral: PMC4159589 | DOI: 10.1002/cbic.201400009

Inset: structure of HIF-1α–p300 complex (PDB ID: 1L8C).

[ 14 ] B) NMR structure (PDB ID: 1L8C)[ 5 ] of p300 in complex with the C-terminal transactivation domain of HIF-1α (top) and excised C-terminal helix of HIF-1α showing key side chains (bottom).

A published NMR structure (PDB ID: 1L8C) of the HIF-1α–p300 complex[ 5 ] ( Figure 1 B ) has shown that the HIF-1α C-terminal transactivation domain (C-TAD) adopts an α-helical conformation and wraps itself around the CH1 domain of p300 with the reported key residues on helices 2 and 3[ 20 ] displayed on one face, making them an obvious target for inhibition with designed ligands[ 21 ] such as constrained peptides,[ 22 , 23 ] β-peptides[ 24 ] or helix mimetics.

[ 29 – 34 ] Using the NMR structure (PDB ID: 1L8C) of the HIF-1α–p300 complex,[ 4 ] we designed and synthesised compounds intended to mimic the key functionalities and spatial orientation of the C-terminal helix (helix 3) of HIF-1α.

Publication Year: 2014


PubMed ID is not available.

Published in 2014

PubMedCentral: PMC4353027

(a) Overlay of HIF1α helix 776–826 (in magenta) and OHM 21 (cyan) in complex with CH1 domain of p300/CBP (PDB code 1L8C).

Experimental Section Docking and Design Protocol in Rosetta The oxopiperazine dimer scaffold was initially docked by aligning Cβ atoms on the scaffold positions corresponding to hotspot residues on P53 (R 1 , Phe19, R 2 , Trp23, R 3 , Leu26) and HIF1α (R 1 , Leu818, R 2 , Leu822, R 4 , Gln824) using the PDB structure: 1YCR and 1L8C, respectively.

Publication Year: 2014